BACKGROUND: Neuroblastoma is a malignant condition of the developing sympathetic nervous system that most commonly affects young children and is often lethal. Its cause is not known. METHODS: We performed a genomewide association study by first genotyping blood DNA samples from 1032 patients with neuroblastoma and 2043 control subjects of European descent using the Illumina HumanHap550 BeadChip. Samples from three independent groups of patients with neuroblastoma (a total of 720 patients) and 2128 control subjects were then genotyped to replicate significant associations. RESULTS: We observed a significant association between neuroblastoma and the common minor alleles of three consecutive single-nucleotide polymorphisms (SNPs) at chromosome band 6p22 and containing the predicted genes FLJ22536 and FLJ44180 (P=1.71x10(-9) to 7.01x10(-10); allelic odds ratio, 1.39 to 1.40). Homozygosity for the at-risk G allele of the most significantly associated SNP, rs6939340, resulted in an increased likelihood of the development of neuroblastoma (odds ratio, 1.97; 95% confidence interval, 1.58 to 2.45). Subsequent genotyping of the three 6p22 SNPs in three independent case series confirmed our observation of an association (P=9.33x10(-15) at rs6939340 for joint analysis). Patients with neuroblastoma who were homozygous for the risk alleles at 6p22 were more likely to have metastatic (stage 4) disease (P=0.02), amplification of the MYCN oncogene in the tumor cells (P=0.006), and disease relapse (P=0.01). CONCLUSIONS: A common genetic variation at chromosome band 6p22 is associated with susceptibility to neuroblastoma. 2008 Massachusetts Medical Society
BACKGROUND:Neuroblastoma is a malignant condition of the developing sympathetic nervous system that most commonly affects young children and is often lethal. Its cause is not known. METHODS: We performed a genomewide association study by first genotyping blood DNA samples from 1032 patients with neuroblastoma and 2043 control subjects of European descent using the Illumina HumanHap550 BeadChip. Samples from three independent groups of patients with neuroblastoma (a total of 720 patients) and 2128 control subjects were then genotyped to replicate significant associations. RESULTS: We observed a significant association between neuroblastoma and the common minor alleles of three consecutive single-nucleotide polymorphisms (SNPs) at chromosome band 6p22 and containing the predicted genes FLJ22536 and FLJ44180 (P=1.71x10(-9) to 7.01x10(-10); allelic odds ratio, 1.39 to 1.40). Homozygosity for the at-risk G allele of the most significantly associated SNP, rs6939340, resulted in an increased likelihood of the development of neuroblastoma (odds ratio, 1.97; 95% confidence interval, 1.58 to 2.45). Subsequent genotyping of the three 6p22 SNPs in three independent case series confirmed our observation of an association (P=9.33x10(-15) at rs6939340 for joint analysis). Patients with neuroblastoma who were homozygous for the risk alleles at 6p22 were more likely to have metastatic (stage 4) disease (P=0.02), amplification of the MYCN oncogene in the tumor cells (P=0.006), and disease relapse (P=0.01). CONCLUSIONS: A common genetic variation at chromosome band 6p22 is associated with susceptibility to neuroblastoma. 2008 Massachusetts Medical Society
Authors: Shaun Purcell; Benjamin Neale; Kathe Todd-Brown; Lori Thomas; Manuel A R Ferreira; David Bender; Julian Maller; Pamela Sklar; Paul I W de Bakker; Mark J Daly; Pak C Sham Journal: Am J Hum Genet Date: 2007-07-25 Impact factor: 11.025
Authors: A F Olshan; A J De Roos; K Teschke; J P Neglia; D O Stram; B H Pollock; R P Castleberry Journal: Cancer Causes Control Date: 1999-12 Impact factor: 2.506
Authors: John M Maris; Matthew J Weiss; Yael Mosse; George Hii; Chun Guo; Peter S White; Michael D Hogarty; Tamar Mirensky; Garrett M Brodeur; Timothy R Rebbeck; Margrit Urbanek; Suzanne Shusterman Journal: Cancer Res Date: 2002-11-15 Impact factor: 12.701
Authors: P Mathew; M B Valentine; L C Bowman; S T Rowe; M B Nash; V A Valentine; S L Cohn; R P Castleberry; G M Brodeur; A T Look Journal: Neoplasia Date: 2001 Mar-Apr Impact factor: 5.715
Authors: A J De Roos; A F Olshan; K Teschke; C Poole; D A Savitz; J Blatt; M L Bondy; B H Pollock Journal: Am J Epidemiol Date: 2001-07-15 Impact factor: 4.897
Authors: S H Friend; R Bernards; S Rogelj; R A Weinberg; J M Rapaport; D M Albert; T P Dryja Journal: Nature Date: 1986 Oct 16-22 Impact factor: 49.962
Authors: Edward F Attiyeh; Sharon J Diskin; Marc A Attiyeh; Yaël P Mossé; Cuiping Hou; Eric M Jackson; Cecilia Kim; Joseph Glessner; Hakon Hakonarson; Jaclyn A Biegel; John M Maris Journal: Genome Res Date: 2009-01-13 Impact factor: 9.043
Authors: Charles C Chung; Wagner C S Magalhaes; Jesus Gonzalez-Bosquet; Stephen J Chanock Journal: Carcinogenesis Date: 2009-11-11 Impact factor: 4.944
Authors: Eric R Gamazon; Navin Pinto; Anuar Konkashbaev; Hae Kyung Im; Sharon J Diskin; Wendy B London; John M Maris; M Eileen Dolan; Nancy J Cox; Susan L Cohn Journal: J Natl Cancer Inst Date: 2012-12-14 Impact factor: 13.506